- CLDX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $74.4 million.
- CLDX has traded 244,323 shares today.
- CLDX is trading at 2.31 times the normal volume for the stock at this time of day.
- CLDX is trading at a new low 4.18% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in CLDX with the Ticky from Trade-Ideas. See the FREE profile for CLDX NOW at Trade-Ideas More details on CLDX: Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Celldex Therapeutics has been 3.1 million shares per day over the past 30 days. Celldex has a market cap of $2.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 3.37 and a short float of 24.4% with 5.74 days to cover. Shares are up 22% year-to-date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Highlights from the ratings report include:
- CELLDEX THERAPEUTICS INC's earnings per share declined by 6.9% in the most recent quarter compared to the same quarter a year ago. Stable earnings per share over the past year indicate the company has managed its earnings and share float. We anticipate this stability to falter in the coming year and, in turn, the company to deliver lower earnings per share than prior full year. During the past fiscal year, CELLDEX THERAPEUTICS INC reported poor results of -$1.03 versus -$1.02 in the prior year. For the next year, the market is expecting a contraction of 28.1% in earnings (-$1.32 versus -$1.03).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has decreased by 21.4% when compared to the same quarter one year ago, dropping from -$23.14 million to -$28.08 million.
- Net operating cash flow has significantly decreased to -$26.59 million or 52.35% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- Reflecting the weaknesses we have cited, including the decline in the company's earnings per share, CLDX has underperformed the S&P 500 Index, declining 24.27% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Biotechnology industry and the overall market, CELLDEX THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Celldex Therapeutics Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.